Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin Z(HER2:2891)-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain
2015 (English)In: International Journal of Oncology, ISSN 1019-6439, Vol. 47, no 2, 601-609 p.Article in journal (Refereed) Published
Development of cancer treatment regimens including immunotoxins is partly hampered by their immunogenicity. Recently, deimmunized versions of toxins have been described, potentially being better suited for translation to the clinic. In this study, a recombinant tripartite fusion toxin consisting of a deimmunized version of exotoxin A from Pseudomonas aeruginosa (PE38) genetically fused to an affibody molecule specifically interacting with the human epidermal growth factor receptor 2 (HER2), and also an albumin binding domain (ABD) for half-life extension, has been produced and characterized in terms of functionality of the three moieties. Biosensor based assays showed that the fusion toxin was able to interact with human and mouse serum albumin, but not with bovine serum albumin and that it interacted with HER2 (K-D=5 nM). Interestingly, a complex of the fusion toxin and human serum albumin also interacted with HER2 but with a somewhat weaker affinity (K-D=12 nM). The IC50-values of the fusion toxin ranged from 6 to 300 pM on SKOV-3, SKBR-3 and A549 cells and was lower for cells with higher surface densities of HER2. The fusion toxin was found specific for HER2 as shown by blocking available HER2 receptors with free affibody molecule before subjecting the cells to the toxin. Analysis of contact time showed that 10 min was sufficient to kill 50% of the cells. In conclusion, all three regions of the fusion toxin were found to be functional.
Place, publisher, year, edition, pages
2015. Vol. 47, no 2, 601-609 p.
affibody molecule, immunotoxin, albumin binding domain, PE38, HER2
Cancer and Oncology
IdentifiersURN: urn:nbn:se:kth:diva-171879DOI: 10.3892/ijo.2015.3027ISI: 000357965700022ScopusID: 2-s2.0-84932646862OAI: oai:DiVA.org:kth-171879DiVA: diva2:846450
FunderSwedish Cancer Society
QC 201508172015-08-172015-08-102015-08-17Bibliographically approved